CN103756903A - Three-dimensional culture system for screening liver-caner chemotherapeutic drugs - Google Patents
Three-dimensional culture system for screening liver-caner chemotherapeutic drugs Download PDFInfo
- Publication number
- CN103756903A CN103756903A CN201410012398.0A CN201410012398A CN103756903A CN 103756903 A CN103756903 A CN 103756903A CN 201410012398 A CN201410012398 A CN 201410012398A CN 103756903 A CN103756903 A CN 103756903A
- Authority
- CN
- China
- Prior art keywords
- culture system
- dimensional culture
- chemotherapy
- gel
- hepatocellular carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/20—Material Coatings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Immunology (AREA)
- Clinical Laboratory Science (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
The invention relates to a three-dimensional culture system for screening liver-caner chemotherapeutic drugs. Furthermore, the invention relates to an application of the three-dimensional culture system in screening the liver-caner chemotherapeutic drugs.
Description
Technical field
The present invention relates to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening.Further, the present invention relates to for individuation screen the dimensional culture system of chemotherapy of hepatocellular carcinoma medicine.
Background technology
Hepatocellular carcinoma is that sickness rate is in tertiary malignant tumour.Cure at present the effective ways of hepatocellular carcinoma.But owing to lacking effective early diagnosis index, during most diagnosing cancer of liver in progressive stage, liver cancer recurrence after excision, these factors have affected the prognosis of liver cancer treatment.Trans-hepatic artery injection chemotherapeutics or whole body treatment with chemotherapy medicine contribute to improve liver cancer patient prognosis.Due to the existence of individuation difference, be not that all patient's liver cancer cells are all to medicaments insensitive used in traditional chemotherapy regimen.Susceptibility chemotherapeutics before treatment with chemotherapy medicine how, thereby the prognosis that improves chemotherapeutic treatment, reducing caused by chemotherapeutic medicines side reaction and being needs the problem that solves in liver cancer treatment.
Chemotherapy of hepatocellular carcinoma treatment at present is only calculated Different Individual chemotherapeutics dosage used or conventional cell culture technology screening chemotherapeutics according to chemotherapy regimen.Yet aforesaid method is acomia, filter out susceptibility chemotherapeutics, and the internal milieu that cell in vitro culture technique can not perfect simulation tumor tissues, cannot accomplish individualized treatment, before treatment with chemotherapy medicine, filter out liver cancer susceptibility chemotherapeutics.
In order to overcome above-mentioned defect of the prior art, the invention provides a kind ofly for screening the dimensional culture system of anti-chemotherapy of hepatocellular carcinoma medicine, utilize the gel contain substratum to construct the support of tumor tissue growth.Liver cancer tissue is fixed in gel stent, liver cancer tissue piece self formed with body on all four tumor tissue growth microenvironment.And gel stent is simulated and the condition of liver cancer tissue at bulk-growth is provided.In dimensional culture system, hepatoma cell proliferation can moving, has got rid of the contact inhibition effect in two-dimentional culture systems, the liver cancer cell growth in this system, complete reaction the reaction of tumour cell to intervening measure.
According to dimensional culture system provided by the invention and prior art shape ratio, have the following advantages:
1, dimensional culture system is established as the culture systems that cell and tissue culture provides a kind of 3 D stereo, the biological behaviour that more meets Growth of Cells, can promote the gathering of cell, maintain histiocytic spheroid-like, and support the normal growth of tumour cell.
2, this technology is utilized three-dimensional histoculture technology, intact simulation live body environment.Compare with conventional cell culture technique, three-dimensional histoculture technology, can simulate the microenvironment of tumor tissues, and the more perfect tumor tissues that presents is to chemotherapy drug susceptibility.
3, native system gathers the liver cancer sample of excision, and for each individuality, the susceptibility of every kind of tumour is screened.Accomplish individuation, at utmost increased chemosensitivity, alleviated toxic and side.
4, native system can be used in stem cell cultivation and breaks up acute and chronic toxicity test; The screening of medicine prediction curative effect; Vasculogenesis test etc.
Summary of the invention
The invention provides a kind of dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening, it is characterized in that, described dimensional culture system contains the gel as liver cancer tissue growth support.
Especially, according to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening of the present invention, it is characterized in that, described dimensional culture system also contains substratum, setting accelerator.
Especially, according to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening provided by the invention, it is characterized in that, described dimensional culture system further contains liver cancer tissue.
Especially, according to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening provided by the invention, it is characterized in that, described liver cancer tissue is fixed in gel stent.
On the other hand, the invention provides a kind of foundation for the method for the dimensional culture system of chemotherapy of hepatocellular carcinoma drug screening, it comprises step:
A) mixture of obtaining liq gel and setting accelerator;
B) gel mixture configuring is added in culture plate, wait for that liquid gel forms translucent;
C) liver cancer tissue piece is positioned in translucent gel, is placed in center, hole, standing, treat that tissue culture gel formation is opaque gelatin.
On the other hand, the invention provides the dimensional culture system prepared according to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening of the present invention or method of the present invention in the purposes of chemotherapy of hepatocellular carcinoma drug screening.
Accompanying drawing explanation
Fig. 1: liver cancer tissue dimensional culture, Microscopic observation different treatment group, liver cancer cell growth and cell migration situation, cell migration is apart from having reacted liver cancer cell to chemotherapy drug susceptibility.Chemotherapy medicament sensitive, cell migration distance is short.A is control group, and B-D is different chemotherapeutics treatment group.
Fig. 2 A to Fig. 2 F utilizes dimensional culture system, filters out different patient's liver cancer tissue susceptibility chemotherapeutics.After it shows that different liver cancer patient liver cancer tissues are cultivated in dimensional culture system, application Pirarubicin (E), Fluracil (F), oxaliplatin (P) or Pirarubicin associating Fluracil (EF), Pirarubicin associating oxaliplatin (EP), Fluracil associating oxaliplatin (FP) or three kinds of chemotherapy drugs in combination application (EFP), the distance that liver cancer cell moves in dimensional culture system.
Should understand, appended accompanying drawing has not shown the technique of painting of slightly simplifying of the exemplifying various features of ultimate principle of the present invention pari passu.Specific design feature of the present invention disclosed herein for example comprises that concrete size, direction, position and profile will partly will be applied and the environment of use is determined by concrete.
In these figures, run through several figures of accompanying drawing, Reference numeral is quoted part same or that be equal to of the present invention.
Embodiment
Dimensional culture system provided by the invention is to utilize the gel that contains substratum to construct the support of liver cancer tissue growth.Liver cancer tissue is fixed in gel stent, liver cancer tissue piece self formed with body on all four tumor tissue growth microenvironment.And gel stent is simulated and the condition of tumor tissues at bulk-growth is provided.In dimensional culture system, hepatoma cell proliferation can moving, has got rid of the contact inhibition effect in two-dimentional culture systems, the growth of tumour cell in this system, complete reaction tumour cell to the reaction of intervening measure (Fig. 1).
The foundation of embodiment 1, dimensional culture system
First prepare tissue culture gel: the setting accelerator (Adittive 1) that 1.5mL is contained to Urogastron adds 12mL tissue culture with in matrigel, described matrigel contains layer and is adhered albumen, collagen iv, fibroblast growth factor, tissue fibers proenzyme activation factor, slowly add, limit edged fully mixes, and mixed solution is faint yellow limpid.The indicator that 1.5mL is contained to phenolphthalein (Adittive 2) adds in mixed solution, and limit slowly adds, and limit mixes.Just added fashionablely, visible topical solutions be pink, becomes faint yellow, limpidly after mixing, and after each component mixes, is configured to 15mL tissue culture gel.
The gel configuring is added in 48 well culture plates, and every hole adds 250uL gel.Be positioned in super clean bench, wait for that liquid gel forms translucent.
The liver cancer tissue sample that extracts excision, is positioned over tissue in PBS solution, is separated into 0.5cm
3size tissue block.
Tissue block is positioned in translucent gel, is placed in center, hole, standing, treat that tissue culture gel formation is opaque gelatin.
In 12mL substratum, add 3mL foetal calf serum.In each tissue culture hole, add 250uL to contain the substratum of foetal calf serum.
Embodiment 2, utilize dimensional culture system to detect the susceptibility of liver cancer tissue to chemotherapeutics
Utilize substratum or PBS to prepare chemotherapeutics to be measured, according to working concentration shown in medicine specification sheets, keep culture volume and chemotherapeutics volume ratio to be greater than 100.
Tumor tissue is cultivated in culture systems to 24h, 48h, 72h, 96h and 120h, every day, observation of cell growing state, and measured cell migration distance.
Collect related data.The impact of statistical study different pharmaceutical on growth of tumour cell and migration.
We utilize above-mentioned three-dimensional histoculture technology, and Hepatocellular Carcinoma is studied to (Fig. 2 A-2F) to chemotherapy drug susceptibility.
Claims (7)
1. for a dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening, it is characterized in that, described dimensional culture system contains the gel as liver cancer tissue growth support.
2. the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening according to claim 1, is characterized in that, described dimensional culture system also contains substratum, setting accelerator.
3. according to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening described in claim 1 or 2 any one, it is characterized in that, described dimensional culture system further contains liver cancer tissue.
4. according to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening described in claim 1 or 3 any one, it is characterized in that, described gel contains layer and is adhered albumen, collagen iv, fibroblast growth factor, tissue fibers proenzyme activation factor.
5. according to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening described in claim 1-4 any one, it is characterized in that, described liver cancer tissue is fixed in gel stent.
6. foundation is for a method for the dimensional culture system of chemotherapy of hepatocellular carcinoma drug screening, and it comprises step:
A) mixture of obtaining liq gel and setting accelerator;
B) gel mixture configuring is added in culture plate, wait for that liquid gel forms translucent;
C) liver cancer tissue piece is positioned in translucent gel, is placed in center, hole, standing, treat that tissue culture gel formation is opaque gelatin.
7. the dimensional culture system of preparing according to the dimensional culture system for chemotherapy of hepatocellular carcinoma drug screening described in claim 1-5 any one or method according to claim 6 is in the purposes of chemotherapy of hepatocellular carcinoma drug screening.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410012398.0A CN103756903A (en) | 2014-01-10 | 2014-01-10 | Three-dimensional culture system for screening liver-caner chemotherapeutic drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410012398.0A CN103756903A (en) | 2014-01-10 | 2014-01-10 | Three-dimensional culture system for screening liver-caner chemotherapeutic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103756903A true CN103756903A (en) | 2014-04-30 |
Family
ID=50524231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410012398.0A Pending CN103756903A (en) | 2014-01-10 | 2014-01-10 | Three-dimensional culture system for screening liver-caner chemotherapeutic drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103756903A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105219730A (en) * | 2015-11-10 | 2016-01-06 | 昭衍（苏州）新药研究中心有限公司 | Ovarian cancer cancerous tissue 3D cultural method and the application in evaluating drug effect thereof |
| CN106337078A (en) * | 2016-10-13 | 2017-01-18 | 成都无界精准生物科技有限公司 | Novel method for detecting sensitivity of tumor medicine |
| CN106676074A (en) * | 2017-03-17 | 2017-05-17 | 南京鼓楼医院 | Method for inducing liver cell cells to be transformed into liver cancer stem cells |
| CN106755261A (en) * | 2016-11-11 | 2017-05-31 | 四川精准医疗科技有限责任公司 | A kind of large intestine carcinoma method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954887A (en) * | 2005-10-28 | 2007-05-02 | 中国科学院大连化学物理研究所 | Preparation method of screening mould of external anti-tumor medicine |
| CN103477222A (en) * | 2010-09-29 | 2013-12-25 | 麻省理工学院 | Device for high throughput investigations of cellular interactions |
-
2014
- 2014-01-10 CN CN201410012398.0A patent/CN103756903A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954887A (en) * | 2005-10-28 | 2007-05-02 | 中国科学院大连化学物理研究所 | Preparation method of screening mould of external anti-tumor medicine |
| CN103477222A (en) * | 2010-09-29 | 2013-12-25 | 麻省理工学院 | Device for high throughput investigations of cellular interactions |
Non-Patent Citations (2)
| Title |
|---|
| BD: "Product Specification Sheet", 《BD BIOSCIENCES DISCOVERY LABWARE》 * |
| 孙培鸣: "体外三维肿瘤模型的研究进展", 《解放军医学院学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105219730A (en) * | 2015-11-10 | 2016-01-06 | 昭衍（苏州）新药研究中心有限公司 | Ovarian cancer cancerous tissue 3D cultural method and the application in evaluating drug effect thereof |
| CN106337078A (en) * | 2016-10-13 | 2017-01-18 | 成都无界精准生物科技有限公司 | Novel method for detecting sensitivity of tumor medicine |
| CN106755261A (en) * | 2016-11-11 | 2017-05-31 | 四川精准医疗科技有限责任公司 | A kind of large intestine carcinoma method |
| CN106676074A (en) * | 2017-03-17 | 2017-05-17 | 南京鼓楼医院 | Method for inducing liver cell cells to be transformed into liver cancer stem cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harsha et al. | Targeting AKT/mTOR in oral cancer: mechanisms and advances in clinical trials | |
| Eikawa et al. | Immune-mediated antitumor effect by type 2 diabetes drug, metformin | |
| Fisher et al. | Three‐dimensional culture models to study drug resistance in breast cancer | |
| Ozcelikkale et al. | Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model | |
| Barbone et al. | Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids | |
| Hussein et al. | Three dimensional culture of HepG2 liver cells on a rat decellularized liver matrix for pharmacological studies | |
| Rao et al. | Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells | |
| Seo et al. | Triculture model of in vitro BBB and its application to study BBB‐associated chemosensitivity and drug delivery in glioblastoma | |
| Sensi et al. | Recellularized colorectal cancer patient-derived scaffolds as in vitro pre-clinical 3D model for drug screening | |
| Samuel et al. | Counteracting chemoresistance with metformin in breast cancers: targeting cancer stem cells | |
| Shin et al. | Characterization of cell-type-specific drug transport and resistance of breast cancers using tumor-microenvironment-on-chip | |
| CN103756903A (en) | Three-dimensional culture system for screening liver-caner chemotherapeutic drugs | |
| CN102822676A (en) | Methods for predicting response of triple-negative breast cancer to therapy | |
| Cerquetti et al. | Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells | |
| Walter et al. | Tesmilifene modifies brain endothelial functions and opens the blood–brain/blood–glioma barrier | |
| Pinto-Leite et al. | mTOR inhibitors in urinary bladder cancer | |
| US20220042975A1 (en) | Methods of generating organoids for high throughput screening of drugs | |
| Fan et al. | Mechanism of modulation through PI3K-AKT pathway about Nepeta cataria L.’s extract in non-small cell lung cancer | |
| CN103756904A (en) | Three-dimensional culture system for tumor cell culture | |
| CN105219730A (en) | Ovarian cancer cancerous tissue 3D cultural method and the application in evaluating drug effect thereof | |
| Maria et al. | Effects of doxorubicin, cisplatin, and tamoxifen on the metabolic profile of human breast cancer MCF-7 cells as determined by 1H high-resolution magic angle spinning nuclear magnetic resonance | |
| Wang et al. | Exosomes as Mediators of Cell‐to‐Cell Communication in Thyroid Disease | |
| de Bem Prunes et al. | The role of tumor acidification in aggressiveness, cell dissemination and treatment resistance of oral squamous cell carcinoma | |
| Lee et al. | A mechanistic study on the anti-cancer activity of ethyl caffeate in human ovarian cancer SKOV-3 cells | |
| Pustovalova et al. | The CD44high subpopulation of multifraction irradiation-surviving NSCLC cells exhibits partial EMT-program activation and DNA damage response depending on their p53 status |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140430 |